Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer
|ClinicalTrials.gov Identifier: NCT00005623|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : March 26, 2013
RATIONALE: Cyproterone acetate may be effective treatment for hot flashes following surgical or chemical castration for prostate cancer. It is not yet known which regimen of cyproterone acetate is more effective for hot flashes.
PURPOSE: Randomized phase III trial to determine the effectiveness of cyproterone acetate in treating patients who have hot flashes following surgical or chemical castration for prostate cancer.
|Condition or disease||Intervention/treatment||Phase|
|Hot Flashes Prostate Cancer||Drug: cyproterone acetate Procedure: quality-of-life assessment||Phase 3|
- Determine the efficacy of cyproterone acetate in patients with hot flashes following bilateral orchiectomy or medical castration for prostate cancer.
- Compare the effectiveness of two doses of cyproterone acetate in these patients.
- Determine the safety of this regimen in these patients.
- Determine the impact of this regimen on the quality of life of these patients.
OUTLINE: This is a randomized, double-blind, placebo controlled study.
Patients receive one of two doses of oral cyproterone acetate or placebo for 12 weeks, followed by a 6-9 month open label extension period with all patients receiving cyproterone acetate.
Quality of life is assessed.
PROJECTED ACCRUAL: Not specified
|Study Type :||Interventional (Clinical Trial)|
|Primary Purpose:||Supportive Care|
|Official Title:||A Phase III, Randomized, Multicenter, Placebo-Controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of CyPat (Cyproterone Acetate [CA]) for the Treatment of Hot Flashes Following Surgical or Chemical Castration of Prostate Cancer Patients and Its Impact on the Quality of Life in These Patients|
|Study Start Date :||December 1999|
|Actual Study Completion Date :||January 2004|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005623
|United States, New York|
|Barr Laboratories, Incorporated|
|Pomona, New York, United States, 10970-0519|
|Study Chair:||Ronald W. Lewis, MD||MBCCOP - Medical College of Georgia Cancer Center|